GPR87 is a G protein-coupled receptor with emerging roles in cancer progression and fibrotic disease. Primary function: GPR87 acts as a lysophosphatidic acid (LPA) receptor 1, though its status as an orphan receptor remains debated 2. Mechanism: GPR87 promotes tumor cell invasion and migration through epithelial-mesenchymal transition, evidenced by increased Vimentin and N-cadherin with decreased E-cadherin expression 3. In renal and pulmonary fibrosis, GPR87 accelerates glycolysis and mitochondrial injury via YAP-hexokinase-2 signaling 4. In esophageal squamous cell carcinoma, GPR87 promotes angiogenesis by regulating VEGFA expression through STAT3 phosphorylation 5. Disease relevance: GPR87 expression is significantly elevated in multiple malignancies and chr3 kidney disease tissues 4, serving as a basal cell marker in idiopathic pulmonary fibrosis honeycomb cysts 6. Genetic variants in GPR87 were identified in familial pulmonary fibrosis kindreds 7. Clinical significance: High GPR87 expression predicts poor overall survival, progression-free interval, and disease-specific survival in lung adenocarcinoma patients 3, correlating with immune infiltration and therapeutic resistance. Targeting GPR87 represents a potential therapeutic strategy for cancer and chr3 kidney disease.